title: Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.
abstract: Bone metastases of gastroenteropancreatic neuroendocrine tumors (GEP NET) can be associated with pain and a poor prognosis. Peptide receptor radionuclide therapy (PRRT) has been shown to be effective against this tumor manifestation. This study represents an update of the therapeutic assessment of PRRT with (177)Lu-octreotate in GEP NET patients with bone metastases focusing on potential predictors for impaired outcome and overall survival.We retrospectively analyzed a consecutive subgroup of n=68 patients with bone metastases (BM) of GEP NET treated with (177)Lu-octreotate (4 intended cycles at 3 monthly intervals; mean activity per cycle, 8.1 GBq). Baseline characteristics, including age, performance status, tumor origin, tumor load, plasma chromogranin A (CgA), and neuron-specific enolase (NSE) were analyzed regarding the impact on tumor regression (modified M.D. Anderson criteria) and survival of the patients. Survival analyses were performed using Kaplan-Meier curves, log-rank test at a significance level of p <0.05, and Cox proportional hazards model for uni- and multivariate analyses. Median follow-up was 48 months. The observed response of BMs consisted of complete remission in 2 (2.9%), partial remission in 23 (33.8%), minor response in 8 (11.8%), stable disease in 26 (38.2%), and progressive disease in 8 (13.2%) patients. Median time-to-progression (TTP) of BMs and overall survival (OS) were 35 mo (95% CI: 25-45) and 51 mo (95% CI: 38-64), respectively. Patients with responding BMs survived significantly longer than other patients (median 56 mo vs. 39 mo, p=0.034). NSE >15 ng/ml (p=0.002) and Ki67 index >10% (p=0.008) were associated with shorter overall survival. BM of GEP NET are effectively controlled by PRRT with a long median progression-free survival of approx. 3 years. Non-regression of BM, high proliferation rate and increased plasma NSE at baseline are predictive of shorter survival. However, this study confirms that poor patient condition (Karnofsky-Index ≤70%) and multifocality of BM (>10 lesions) do not affect outcome efficacy, further encouraging the use of PRRT in advanced bone metastatic disease.
authors.affiliation: Department of Nuclear Medicine, University Hospital Bonn, Germany.
authors.forename: Amir
authors.initials: A
authors.lastname: Sabet
authors.forename: Feras
authors.initials: F
authors.lastname: Khalaf
authors.forename: Torjan
authors.initials: T
authors.lastname: Haslerud
authors.forename: Abdullah
authors.initials: A
authors.lastname: Al-Zreiqat
authors.forename: Amin
authors.initials: A
authors.lastname: Sabet
authors.forename: Birgit
authors.initials: B
authors.lastname: Simon
authors.forename: Thorsten D
authors.initials: TD
authors.lastname: Pöppel
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Biersack
authors.forename: Samer
authors.initials: S
authors.lastname: Ezziddin
keywords: Bone metastases; gastroenteropancreatic neuroendocrine tumors (GEP NET); peptide receptor radionuclide therapy (PRRT)